Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone

被引：0
|
作者：
Harousseau, J. L.
Nagler, A.
Sonneveld, P.
Blade, J.
Hajek, R.
Spencer, A.
Robak, T.
Xiu, L.
Zhuang, S. H.
Orlowski, R. Z.
机构：
[1] Hoteldieu Hosp, Nantes, France
[2] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[3] Erasmus MC, Rotterdam, Netherlands
[4] Hosp Clin I Prov, Barcelona, Spain
[5] Interni Hematoonkol Klin Fak Brno, Brno, Czech Republic
[6] Alfred Hosp, Melbourne, Vic, Australia
[7] Med Univ Lodz, Lodz, Poland
[8] Johnson & Johnson PRD, Raritan, NJ USA
[9] Univ N Carolina, Chapel Hill, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8002
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Early normalization of serum free light chain is associated with prolonged time to progression following bortezomib ± pegylated liposomal doxorubicin treatment of relapsed/refractory multiple myeloma
    Orlowski, Robert
    Sutherland, Heather
    Blade, Jean
    San Miguel, Jesus
    Hajek, Roman
    Nagler, Arnon
    Sonneveld, Pieter
    Spencer, Andrew
    Robak, Tadeusz
    Mundle, Suneel
    Luo, Donghan
    Zhuang, Sen Hong
    Harousseau, Jean-Luc
    BLOOD, 2007, 110 (11) : 803A - 804A
  • [32] Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone
    Jagannath, Sundar
    Richardson, Paul G.
    Barlogie, Bart
    Berenson, James R.
    Singhal, Seema
    Irwin, David
    Srkalovic, Gordan
    Schenkein, David P.
    Esseltine, Dixie L.
    Anderson, Kenneth C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (07): : 929 - 934
  • [33] COMBINATION OF THALIDOMIDE, PEGYLATED LIPOSOMAL DOXORUBICIN, DEXAMETHASONE AND BORTEZOMIB (THADD-V) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: RESULTS OF A PHASE II STUDY
    Offidani, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 153 - 153
  • [34] PEGYLATED LIPOSOMAL DOXORUBICIN IN COMBINATION WITH BORTEZOMIB FOR THE TREATMENT OF RELAPSED MULTIPLE MYELOMA-A COST-EFFECTIVENESS STUDY FOR SCOTLAND
    Gibbons, C. J.
    Yong, K.
    Roberts, G.
    VALUE IN HEALTH, 2008, 11 (06) : A467 - A467
  • [35] BORTEZOMIB IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN AND THALIDOMIDE (VDT) FOR THE TREATMENT OF PREVIOUSLY UNTREATED MULTIPLE MYELOMA
    Ailawadhi, S.
    Miller, K. C.
    Depaolo, D.
    Whitworth, A.
    Yu, J.
    Trump, D. L.
    Padmanabhan, S.
    Czuczman, M.
    Bernstein, Z. P.
    Hernandez-Ilizaliturri, F.
    Lee, K.
    Chanan-Khan, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 83 - 83
  • [36] Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide (VDT) for the treatment of previously untreated multiple myeloma
    Chanan-Khan, Asher A.
    Miller, Kena C.
    DePaolo, Dawn
    Padmanabhan, Swaminathan
    Whitworth, Amy
    Ailawadhi, Sikander
    Lee, Kelvin
    Czuczman, Myron S.
    BLOOD, 2007, 110 (11) : 1057A - 1058A
  • [37] A retrospective review of pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone (DVD) for relapsed or refractory (R/R) multiple myeloma (MM)
    Waterman, G. N.
    Yellin, O.
    Swift, R. A.
    Hilger, J.
    Berenson, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone
    Min, C. K.
    Lee, M. J.
    Eom, K. S.
    Lee, S.
    Lee, J. W.
    Min, W. S.
    Kim, C. C.
    Kim, M.
    Lim, J.
    Kim, Y.
    Han, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 156 - 157
  • [39] Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor
    Lentzsch, Suzanne
    Quach, Hang
    Chanan-Khan, Asher A.
    Horvath, Noemi
    Capra, Marcelo
    Ovilla, Roberto
    Jo, Jae-Cheol
    Shin, Ho-Jin
    Thiyagarajah, Piruntha
    Amin, Himal
    Casneuf, Tineke
    Sonneveld, Pieter
    Schecter, Jordan
    Hungria, Vania T. M.
    BLOOD, 2017, 130
  • [40] Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone
    Min, Chang-Ki
    Lee, Mi-Jin
    Eom, Ki-Seong
    Lee, Seok
    Lee, Jong-Wook
    Min, Woo-Sung
    Kim, Chun-Choo
    Kim, Myungshin
    Lim, Jihyang
    Kim, Yonggoo
    Han, Kyungja
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (12) : 961 - 968
12345